EUVIMEDEUVIMED entdecken
Crossref

Identifying COVID ‐19 Disease Severity in Real‐World Data: Implications for Medical Product Effectiveness Studies

Mayura U Shinde, Katherine Shapiro, Laura Hou, Kevin Coughlin, Aaron M Madow, Fatma M Shebl, Patricia Bright, Gaia Pocobelli iD, James D Ralston, Vina F Graham, Margaret B Nolan, Ingrid A Binswanger und 4 weitere

Pharmacoepidemiology and Drug Safety · 2026

DOI: 10.1002/pds.70363 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Pharmacoepidemiology and Drug Safety, 2026. Verfasst von Mayura U Shinde und 15 weiteren Autor:innen. Beteiligte Einrichtung: Department of Population Medicine, Harvard Pilgrim Health Care Institute, Boston, Massachusetts, USA. Hauptthemen laut MEDLINE: Severity of Illness Index, COVID-19, Algorithms, COVID-19 Drug Treatment. Die Arbeit nennt 19 Literaturangaben. Gefördert von: U.S. Food and Drug Administration.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Purpose

The U.S. Food and Drug Administration (FDA) defined disease severity criteria to assist clinical development of medical products for management of COVID‐19. These definitions were translated to code‐based algorithms for use in real‐world data. We validated the algorithms' performance in ambulatory settings at three regional integrated healthcare delivery systems contributing data to FDA's Sentinel System.

Methods

We identified cohorts of individuals ≥ 18 years that met the algorithms' criteria for mild, moderate, and severe COVID‐19 at incident COVID‐19 diagnosis or positive SARS‐CoV‐2 test, and separately, at incident COVID‐19 treatment, from January 2022 through April 2023. We validated the algorithms via chart review of a random sample to calculate positive predictive values (PPVs) and 95% CIs.

Results

The algorithms identified 33 071 patients at COVID‐19 diagnosis or positive test; 26 985 mild (49 chart reviewed), 5180 moderate (55 reviewed), and 906 severe (56 reviewed). A total of 4512 patients were identified at COVID‐19 treatment; 3474 mild (56 reviewed), 848 moderate (60 reviewed), and 190 severe (46 reviewed). The PPVs (1) at COVID‐19 diagnosis or positive test were: mild 57% (95% CI: 43%–71%), moderate 58% (95% CI: 45%–71%), and severe 54% (95% CI: 41%–67%), and (2) at COVID‐19 treatment: mild 57% (95% CI: 44%–70%), moderate 70% (95% CI: 58%–82%) and severe 72% (95% CI: 59%–85%).

Conclusion

The algorithms had low‐to‐moderate performance in classifying COVID‐19 severity in ambulatory settings, depending on assessment at diagnosis or treatment. Researchers should consider the performance of the algorithm when using real‐world data to assess COVID‐19 severity.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Severity of Illness IndexCOVID-19AlgorithmsCOVID-19 Drug TreatmentHumansUnited StatesMiddle AgedFemaleUnited States Food and Drug AdministrationMaleAdultSARS-CoV-2AgedPredictive Value of Tests

Stichwörter der Autor:innen

COVID‐19algorithmspositive predictive valuereal‐world data

Autor:innen und Institutionen

  • Department of Population Medicine, Harvard Pilgrim Health Care Institute, Boston, Massachusetts, USA.
  • Harvard Medical School, Boston, Massachusetts, USA.
  • Office of Surveillance and Epidemiology, Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, Maryland, USA.
  • Kaiser Permanente Washington Health Research Institute, Seattle, Washington, USA.
  • HealthPartners Institute, Bloomington, Minnesota, USA.
  • Kaiser Permanente Colorado, Aurora CO, Colorado Permanente Medical Group, Denver, Colorado, USA.

ORCID-Profile: Gaia Pocobelli, Silvia Perez-Vilar

Förderung

  • U.S. Food and Drug Administration

Zitieren

APA

Shinde, M. U., Shapiro, K., Hou, L., Coughlin, K., Madow, A. M., Shebl, F. M., Bright, P., Pocobelli, G., Ralston, J. D., Graham, V. F., Nolan, M. B., Binswanger, I. A., Pratt, N., Hua, W., Cocoros, N. M., & Perez-Vilar, S. (2026). Identifying COVID ‐19 Disease Severity in Real‐World Data: Implications for Medical Product Effectiveness Studies. Pharmacoepidemiology and Drug Safety. https://doi.org/10.1002/pds.70363

Vancouver

Shinde MU, Shapiro K, Hou L, Coughlin K, Madow AM, Shebl FM, et al. Identifying COVID ‐19 Disease Severity in Real‐World Data: Implications for Medical Product Effectiveness Studies. Pharmacoepidemiology and Drug Safety. 2026. doi:10.1002/pds.70363

BibTeX
@article{Shinde2026,
  author = {Shinde, Mayura U and Shapiro, Katherine and Hou, Laura and Coughlin, Kevin and Madow, Aaron M and Shebl, Fatma M and Bright, Patricia and Pocobelli, Gaia and Ralston, James D and Graham, Vina F and Nolan, Margaret B and Binswanger, Ingrid A and Pratt, Natasha and Hua, Wei and Cocoros, Noelle M and Perez-Vilar, Silvia},
  title = {Identifying COVID ‐19 Disease Severity in Real‐World Data: Implications for Medical Product Effectiveness Studies},
  journal = {Pharmacoepidemiology and Drug Safety},
  year = {2026},
  doi = {10.1002/pds.70363}
}
Infokarte | EUVIMED

Artikeldaten derzeit nicht verfügbar.

Recherche